Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting

Fineline Cube Jun 6, 2023

A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...

Company Deals

Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production

Fineline Cube Jun 6, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...

Company Deals

Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders

Fineline Cube Jun 6, 2023

Private equity firm Longreach Group, which specializes in the Asian market, is in the process...

Company Drug

Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting

Fineline Cube Jun 6, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...

Company Drug

Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma

Fineline Cube Jun 5, 2023

Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...

Company Medical Device

NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...

Company Medical Device

NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...

Company Deals

HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development

Fineline Cube Jun 5, 2023

China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...

Company Deals

Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D

Fineline Cube Jun 5, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm...

Company Drug

Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH

Fineline Cube Jun 5, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...

Company Drug

Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment

Fineline Cube Jun 5, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...

Company Deals

CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation

Fineline Cube Jun 5, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...

Company Drug

Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA

Fineline Cube Jun 5, 2023

Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...

Company Drug

Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage

Fineline Cube Jun 5, 2023

Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...

Policy / Regulatory

CDE Releases 70th Batch of Generic Reference Preparations for Public Feedback

Fineline Cube Jun 5, 2023

The Center for Drug Evaluation (CDE) has released the 70th batch of chemical generic reference...

Company Drug

CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment

Fineline Cube Jun 5, 2023

Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...

Company Deals

Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01

Fineline Cube Jun 5, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...

Company Drug

Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G

Fineline Cube Jun 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...

Company Drug

CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome

Fineline Cube Jun 2, 2023

China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...

Company Deals Drug

Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC

Fineline Cube Jun 2, 2023

China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...

Posts pagination

1 … 473 474 475 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.